ArticleMedicine2025
Sentinel lymph node-related lncRNA typing affects breast cancer prognosis and treatment response through the immune cell microenvironment.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long non-coding RNAs: key orchestrators of macrophage polarization in breast cancer.Cancer cell international · 2025Review
- TFP12 as a key regulator of sentinel lymph node metastasis in breast cancer.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The sentinel lymph node (SLN) plays a crucial role in the early treatment of breast cancer. The present study aims to investigate the impact of SLN-associated long noncoding RNAs (lncRNAs) on breast cancer and the influence of molecular subtyping based on related genes on prognosis. To identify SLN-associated lncRNAs, we conducted differential expression analysis using 2 high-throughput sequencing techniques. In addition, ConsensusClusterPlus was employed to establish lncRNA molecular subtypes. Subsequently, comprehensive analysis using LASSO regression was performed to construct an optimal model for predicting breast cancer prognosis. Finally, various functional annotation databases were utilized to elucidate the potential functions of the predictive model. Through differential expression analysis, we identified 14 SLN-associated lncRNAs. These genes primarily influence TNF signaling pathways. Furthermore, we found that lncRNA H19 is a prominent regulatory factor among these 14 gene expressions. By utilizing ConsensusClusterPlus, we successfully stratified the IR samples into 2 distinct subtypes. Through LASSO regression, we established a prognosis model predominantly impacting various immune cells and drug resistance. After verifying 10 pairs of organizations through PCR, we found differences in 6 lncRNAs between the 2 groups of SNLs. At the same time, in the subsequent analysis of immune infiltration and drug targets, it was found that TRPC2 plays a very critical role in breast cancer. Our study highlights the significance of SLN-associated lncRNAs, unveiling the intricate mechanisms underlying the progression of breast cancer. These findings provide novel insights and potential targets for future therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.